SCHEMBL948019

SCHEMBL948019

Cc1cn(C2CCN(C(=O)OC(C)(C)C)CC2)c(C)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 7/20 0.54
HCAR1 Q9BXC0 1/20 0.47
EPHX1 P07099 1/20 0.45
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44
THRB P10828 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
TP53 P04637 1/20 0.44
HPGD P15428 1/20 0.44
PRKCG P05129 1/20 0.44
PRKCB P05771 1/20 0.44
PRKCA P17252 1/20 0.44
PRKCH P24723 1/20 0.44
PRKCE Q02156 1/20 0.44
PRKCD Q05655 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4719422 0.82 GPR119 (0.39) GPR119HCAR1DDB1CRBNPRKCG
SCHEMBL4792896 0.81 GPR119 (0.43) GPR119HCAR1DDB1CRBNKDM4E
SCHEMBL15824668 0.81 GPR119 (0.49) GPR119KDM4EPTPN2PTPN1PTPN6
SCHEMBL27035854 0.79 HCAR1 (0.49) GPR119HCAR1KDM4EMAPTTHRB
SCHEMBL18376153 0.79 GPR119 (0.47) GPR119DDB1CRBNKDM4EMAPT
SCHEMBL948139 0.79 GPR119 (0.53) GPR119HCAR1EPHX1KDM4EMAPT
SCHEMBL2843409 0.77 HPGDS (0.57) GPR119
SCHEMBL948610 0.76 HCAR1 (0.54) GPR119HCAR1KDM4EMAPTTHRB
SCHEMBL15950964 0.76 GPR119 (0.50) GPR119DDB1CRBNMAPTPTPN2
SCHEMBL12121174 0.76 DDB1 (0.57) GPR119DDB1CRBNTP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-13 US disclosed
US-20070004736-A1 Imidazole derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-01-04 US disclosed
CN-1708493-A Selected CGRP antagonists, method for production and use thereof as medicament BOEHRINGER INGELHEIM PHARMA (DE) 2005-12-14 CN disclosed
EP-1564213-A1 IMIDAZOLE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004736-A1 Imidazole derivative, process for producing the same, and use HRH4, F2, HRH2 GPR119 1327/4885HCAR1 130/4885EPHX1 789/4885
US-20110009389-A1 IMIDAZOLE DERIVATIVE, THEIR PRODUCTION AND USE F2, H1-3, CYC1 GPR119 1118/4885HCAR1 215/4885EPHX1 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.